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High CD21 expression inhibits internalization of anti-CD19
antibodies and cytotoxicity of an anti-CD19-drug conjugate
Non-Hodgkin lymphoma (NHL) is one of the most rapidly
increasing cancers in the United States, with approximately
63 000 new cases predicted for 2007 and a prevalence of
approximately 360 000 (American Cancer Society, 2007). The
most common subtype of NHL (representing approximately
30% of cases) is diffuse large B-cell lymphoma (DLBCL), while
approximately 15% of cases involve the less aggressive
follicular lymphoma (American Cancer Society, 2007). Most
NHLs (85%)involve malignancies of the B-cells, many of which
express the B-cell speciﬁc maturation antigen CD20 (Nadler
et al, 1981). Rituximab (Rituxan , Genentech, Inc., South San
Francisco, CA, USA) is a chimeric anti-CD20 antibody that
shows efﬁcacy against B-cell lymphomas (James & Dubs, 1997)
and has recently been approved as ﬁrst line therapy in
combination with chemotherapy for treatment of CD20
+ NHLs
(Cvetkovic & Perry, 2006). However, some lymphomas lack
CD20 expression and a signiﬁcant number of CD20
+ patients
do not respond to, or acquire resistance to, Rituximab therapy
[reviewed by Smith (2003)], providing a rationale for investi-
gating other targets and therapies for NHL.
One promising strategy for cancer therapy involves coupling
cytotoxic drugs or radionucleotides to tumour-speciﬁc anti-
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Summary
CD19 and CD21 (CR2) are co-receptors found on B-cells and various B-cell
lymphomas, including non-Hodgkin lymphoma. To evaluate their suitability
as targets for therapy of such lymphomas using internalization-dependent
antibody-drug conjugates [such as antibody-4-(N-maleimidomethyl)
cyclohexane-1-carboxylate, (N
2¢-deacetyl-N
2¢-(3-mercapto-1-oxopropyl)-
maytansine) (MCC-DM1) conjugates, which require lysosomal degradation
of the antibody moiety for efﬁcacy], we examined uptake of antibodies to
CD19 and CD21 in a panel of B-cell lines. Anti-CD21 antibodies were not
sufﬁciently internalized even in the highest CD21-expressing Raji cells,
resulting in lack of efﬁcacy with anti-CD21-MCC-DM1 conjugates. Anti-
CD19 antibody uptake was variable, and was unexpectedly negatively
correlated with CD21 expression. Thus, high CD21-expressing Raji, ARH77
and primary B-cells only very slowly internalized anti-CD19 antibodies, while
CD21-negative or low expressing cells, including Ramos and Daudi, rapidly
internalized these antibodies in clathrin-coated vesicles followed by lysosomal
delivery. Anti-CD19-MCC-DM1 caused greater cytotoxicity in the faster
anti-CD19-internalizing cell lines, implying that the rate of lysosomal delivery
and subsequent drug release is important. Furthermore, transfection of
Ramos cells with CD21 impeded anti-CD19 uptake and decreased anti-
CD19-MCC-DM1 efﬁcacy, suggesting that CD21-negative tumours should
respond better to such anti-CD19 conjugates. This may have possible clinical
implications, as anti-CD21 immunohistochemistry revealed only
approximately 30% of 54 diffuse large B-cell lymphoma patients lack CD21
expression.
Keywords: CD19, CD21, CR2, immunoconjugates, non-Hodgkin lym-
phoma, antibody therapy.
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decreasing non-speciﬁc toxicity compared with conventional
chemo- or radiotherapy, as well as improving efﬁcacy com-
pared with naked antibody therapy (Vose, 1999; Polakis,
2005). Antibody-drug conjugates (ADCs) comprise tumour-
speciﬁc antibodies chemically linked to cytotoxic drugs that are
more potent than standard chemotherapeutics, resulting in
excellent anti-tumour effects, but also systemic toxicity or
‘bystander’ effects (killing of nearby antigen-negative cells) if
membrane-permeable drugs are released from the surface of
cancer cells. Such release occurs when readily cleavable linkers
are used, such as the reducible N-Succinimydyl 4-(2-Pyr-
idyldithio) Pentanoate (SPP) linker (Xie et al, 2004; Austin
et al, 2005; Kovtun et al, 2006) and acid-sensitive hydrazone
linkers (Hamann et al, 2002; Doronina et al, 2003). To avoid
non-speciﬁc toxicity, an ideal ADC would comprise a drug
stably attached to the antibody such that the active drug were
only released following internalization into the target cancer
cell. One example is antibody-4-(N-maleimidomethyl)cyclo-
hexane-1-carboxylate (MCC)- (N
2¢-deacetyl-N
2¢-(3-mercapto-
1-oxopropyl)-maytansine) DM1 conjugates employing an
uncleavable thioether succinimidyl-4-(N-maleimidometh-
yl)cyclohexane-1-carboxylate (SMCC) linker (which becomes
MCC following conjugation) between the antibody and the
maytansinoid microtubule polymerization inhibitor, DM1.
However, these conjugates require efﬁcient internalization and
lysosomal degradation of the antibody to release the drug,
which then diffuses within the cell and triggers cell death by
preventing assembly of the mitotic spindle (Erickson et al,
2006). Antibodies to the B-cell receptor component CD79b
internalize rapidly (within 20 min), being delivered to lyso-
somes within an hour and consequently anti-CD79b-MCC-
DM1 conjugates show remarkable efﬁcacy against CD79b-
expressing xenografts (Polson et al, 2007). By contrast, CD20
antibodies are well-known not to internalize signiﬁcantly even
after prolonged incubation (Press et al, 1989, 1994; Sieber
et al, 2003), so CD20 is not an ideal target for such ADCs with
non-surface-cleavable linkers. The trafﬁcking of anti-tumour
antibodies following target binding clearly plays an important
role in linker-drug selection.
CD19 (B4) has a wider expression proﬁle than CD20 on
both normal B-cells and NHL cells (Nadler et al, 1983; Uckun
et al, 1988), and could be a more suitable ADC target as
various anti-CD19 antibodies have been shown to internalize
at different rates in several studies (Uckun et al, 1988; Press
et al, 1989, 1994; Pulczynski et al, 1993; van Oosterhout et al,
1994; Sapra & Allen, 2002). However, other reports show no
signiﬁcant internalization (Ghetie et al, 1997; Cherukuri et al,
2001a; Sieber et al, 2003), and it is unclear whether this is due
to use of different anti-CD19 antibodies, cell types or
experimental conditions. CD19, in a complex with CD81
and CD21, acts as a co-receptor, enhancing signalling and
antigen processing by the B-cell receptor in response to
complement-tagged antigens (Fearon & Carroll, 2000). CD21
(also known as complement receptor 2 [CR2] or B2) is also
associated with at least some B-cell lymphomas (Nadler et al,
1983; Scoazec et al, 1989; Gloghini & Carbone, 1993; Echeverri
et al, 2002) but anti-CD21 antibody internalization has only
been evaluated in a limited number of studies (Pulczynski
et al, 1994; Tessier et al, 2006).
To evaluate the utility of both CD19 and CD21 as targets for
antibody-MCC-DM1 conjugates, we examined the internali-
zation of antibodies to these antigens by immunoﬂuorescence
in several malignant B-cell lines, as well as primary B-cells and
correlated the uptake with sensitivity to the respective
conjugates.
Materials and methods
Antibodies
Unless otherwise indicated, antibodies used were mouse anti-
CD19 (clone B496, Biomeda CB-19; Biomeda, Foster City, CA,
USA) and mouse anti-CD21 [HB135 (American Type Culture
Collection, Manassas, VA, USA), also called THB-5 or HB5],
anti-CD20 (2H7), anti-CD22 (RFB4) and anti-CD79b (SN8),
all afﬁnity puriﬁed at Genentech Inc. (South San Francisco,
CA, USA) from hybridoma supernatants. Other anti-CD19
antibodies were BU12 (AnCell, Bayport, MN, USA), FMC63
(B19; Chemicon, Boronia, Vic., Australia) and HD37 (B4;
Chemicon).
Cell culture
Human B-cell lines were all cultured for a maximum of
2 months in RPMI medium, heat-inactivated 10% fetal bovine
serum (FBS; Hyclone, Logan, UT, USA), 1% l-glutamine and
were mycoplasma-free. Primary B-cells were isolated from
normal human blood using the RosetteSep
  non-B-cell
depletion kit (StemCell Technologies, Vancouver, BC, Canada)
according to the manufacturer’s instructions.
CD21-Ramos generation
Two micrograms untagged CD21 full-length (isoform A,
Swissprot 20023) subcloned into pCMV.PD5 using XbaI and
BamHI (partial digest) was nucleoporated into 2 · 10
6 Ramos
cells in 100 ll Solution T and program O-06 according to the
Amaxa Nucleofector II instructions. After 48 h recovery in
a 12-well dish, cells were selected with 0Æ5 lg/ml puromycin
(CellGro, Herndon, VA, USA) and 1% sodium pyruvate
(Gibco, Carlsbad, CA, USA) for 18–24 d, after which high
expressors were collected by ﬂow cytometry with Alexa488-
HB135 anti-CD21.
Antibody uptake immunoﬂuorescence
Cells were incubated for 5 min to 3 h in complete carbonate-
independent medium (Gibco) in a 37 C waterbath (or in
a5 %C O 2 cell incubator in growth media for longer) with
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(Miltenyi Biotec, Auburn, CA, USA, dialyzed to remove
azide), and 10 lg/ml Alexa488-transferrin or 25 lg/ml
Alexa647-transferrin (Molecular Probes, Carlsbad, CA, USA)
in the presence of 10 lg/ml leupeptin and 5 lmol/l pepstatin
A (Roche Diagnostics, Indianapolis, IN, USA) to inhibit
lysosomal degradation. Cells were then washed, ﬁxed with 3%
paraformaldehyde (Electron Microscopy Sciences, Hatﬁeld,
PA, USA), permeabilized with 0Æ4% saponin and the
internalized antibody detected with 1 lg/ml Cy3 donkey
anti-mouse Fc (Jackson Immunoresearch, West Grove, PA,
USA), sometimes followed by anti-LAMP1 (Lysosomal Asso-
ciated Membrane Protein-1) staining as previously described
(Polson et al, 2007). Slides coverslipped with 4¢,6-diamidino-
2-phenylindole (DAPI)-containing Vectashield were viewed
by epiﬂuorescence microscopy with a DeltaVision
  RT
System (Applied Precision LLC, Issaquah, WA, USA), using
a 100· Olympus UplanoApo objective. Images were captured
with a Photometrics CH350 CCD camera powered by
SoftWorx (version 3Æ4Æ4) software (Applied Precision LLC,
Indianapolis, IN, USA) and assembled in Adobe Photoshop
CS (Adobe Systems, Inc., San Jose, CA, USA).
Surface ﬂow cytometry
Cells were incubated with 2 lg/ml murine monoclonal anti-
bodies to CD19 (B496, IgG1), CD21 (HB135, IgG2a), CD20
(2H7, IgG2a), CD22 (RFB4, IgG1), or CD79b (SN8, IgG1)
with human FcR block in phosphate-buffered saline (PBS)
containing 3% FBS on ice for 30 min, washed twice, then
incubated with phycoerythrin (PE)-conjugated rat anti-mouse
IgG1 or IgG2a + b (Becton Dickinson, Franklin Lakes, NJ,
USA) for 30 min on ice. After two washes, cells were analyzed
[with propidium iodide (PI) exclusion] on a FACSCalibur (BD
Biosciences, San Jose, CA, USA).
Quantitative uptake ﬂow cytometry
Cells were incubated for 30 min at room temperature with
2 lg/ml Alexa488-anti-CD19, human FcR block and lysosomal
protease inhibitors, shifted to 37 C for 20 min to 3 h, washed
twice, and either ﬁxed with 2% paraformaldehyde (PFA) or
surface ﬂuorescence quenched with 25 lg/ml rabbit anti-
Alexa488 (Molecular Probes) for 1 h prior to ﬁxation and
analysis on a FACSCalibur (BD Biosciences). Uptake was
calculated as previously described (Austin et al, 2004) and
normalized to the amount of anti-CD19 initially bound.
Where indicated, endocytic inhibitors were pre-incubated with
cells for 30 min at 37 C at the following concentrations:
2 mmol/l methyl-b-cyclodextrin, 5 lg/ml ﬁlipin, 100 lmol/l
chlorpromazine (all from Sigma Aldrich, St Louis, MO, USA),
except for dynasore (TimTec, Newark, DE, USA), which was
only pre-incubated with cells for 5 min at 80 lmol/l in serum-
free media as reported (Macia et al, 2006). Background of
inhibitor-treated cells without antibody was subtracted from
the raw data prior to normalizing to the dimethyl sulphoxide
(DMSO) control.
Antibody-drug conjugates
Conjugates were synthesized as described (Polson et al, 2007),
except that the antibodies used were the anti-CD21 clone
HB135, anti-CD19 clone B496 and Trastuzumab anti-HER2
(Genentech Inc.). 7Æ5· molar excess SMCC was reacted with
antibody for 4 h prior to DM1 addition, resulting in anti-
CD21-MCC-DM1, anti-CD19-MCC-DM1 and Trastuzumab–
MCC-DM1 conjugates with molar drug:antibody ratios of
4Æ05, 3Æ6 and 2Æ12 respectively.
Cytotoxicity and apoptosis assay
Cells were seeded at 5000/well in 50 ll on clear round-
bottomed 96-well plates and after 24 h were treated with
serially diluted anti-CD19-MCC-DM1, anti-CD21-MCC-
DM1, negative control Trastuzumab-MCC-DM1, naked anti-
body controls, or equivalent amounts of free L-DM1 dimer
(serially diluted from 66Æ6t o0 Æ3 nmol/l), or normal growth
medium at 37 C, 5% CO2. Cell viability and apoptosis were
assessed after 3 and 2 d using the CellTiter Glo and Caspase
Glo 3/7 kits, respectively, according to the manufacturer’s
instructions (Promega, Madison, WI, USA).
Immunohistochemistry
Sections (5 lm) of formalin-ﬁxed, parafﬁn-embedded lym-
phoma tissue microarrays (Cybrdi, Frederick, MD, USA) on
microscope slides were dewaxed and treated with Target
Retrieval solution (Dako, Capinteria, CA, USA) at 99 C for
20 min in a boiling water bath. Endogenous peroxidase activity
was quenched using 1· Blocking Solution (KPL, Gaithersburg,
MD, USA) for 4 min. Sections were treated with Avidin/Biotin
block (Vector) and Blocking Buffer containing 10% normal
horse serum before sequentially incubating with 5 lg/ml anti-
CD21 HB135, biotinylated horse anti-mouse (Vector), avidin-
biotin peroxidase (Vector Labs, Burlingame, CA, USA), and
biotinyl tyramide (Perkin-Elmer Inc., Waltham, MA, USA).
Avidin-biotin peroxidase and diaminobenzidine (Pierce Bio-
technology, Inc., Rockford, IL, USA) were used for detection.
Results
Anti-CD21 antibody HB135 is not signiﬁcantly
internalized
The expression of CD21 in human B-cell lymphomas is
variable (Nadler et al, 1983; Echeverri et al, 2002), most likely
in part because it is the receptor for Epstein–Barr virus (EBV),
as infection with this virus induces high expression of CD21
(CR2) and its co-receptor CD35 (CR1; Freeman et al, 1982;
Cohen et al, 1987). EBV-negative B-cell lymphoma lines, such
G. S. Ingle et al
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levels of surface CD21, while EBV-positive cells like Daudi,
ARH77 and Raji have higher levels (Table I).
The anti-CD21 antibody HB135 (abbreviated as ‘anti-CD21’
throughout) did not appreciably internalize in any B-cell line
tested, irrespective of CD21 expression level (Fig 1A–F), even
though the control co-incubated ﬂuorescent transferrin was
readily taken up (not shown). As expected, SuDHL-4 (not
shown), Ramos and DoHH2 cells, which lack CD21 expression
altogether, did not take up anti-CD21 (Fig 1A,B). However,
even the moderately expressing Namalwa and Daudi cells
(Fig 1C,D) and the higher expressing ARH77 and Raji cells
(Fig 1E,F) failed to signiﬁcantly internalize this antibody. Anti-
CD21 similarly did not appreciably internalize in B-cells freshly
isolated from normal human blood (Fig 1G), with antibodies
mostly remaining at the cell surface similar to their distribu-
tion following incubation for 1 h on ice (insets), at which
temperature all membrane trafﬁc is inhibited. While removal
of surface antibody signal by acid stripping did reveal a small
amount of intracellular anti-CD21 antibody in Raji cells (data
not shown), our experience with other B-cell speciﬁc antibod-
ies showed that much more signiﬁcant uptake (readily
detectable without surface stripping) is required for effective
drug delivery (Polson et al, 2007). The poor anti-CD21 uptake
might explain the lack of efﬁcacy of anti-CD21(HB135)-MCC-
DM1 conjugates (which require good internalization and
lysosomal delivery for drug release) even in the highest CD21-
expressing Raji cells (see later) and ARH77 cells (data not
shown). Taken together, these results suggest that CD21 is not
a suitable target for ADCs requiring good cellular uptake for
efﬁcacy.
Anti-CD19 antibodies only internalize signiﬁcantly in
CD21-negative or low cell lines
Internalization of various anti-CD19 antibodies has been
reported in a number of B-cell lines and clinical samples with
contradictory results (van Oosterhout et al, 1994; Press et al,
1994; Ghetie et al, 1997; Goulet et al, 1997; Sieber et al, 2003).
Dimerization of anti-CD19 antibodies with a chemical linker
(Ghetie et al, 1997), dimeric drug (Goulet et al, 1997) or cross-
linking with secondary antibodies (Sieber et al, 2003) increases
their uptake, but the latter is not relevant to ADC therapy,
since secondary antibodies would not be present in the patient.
We therefore focused on uptake in the absence of cross-linking
of a novel anti-CD19 monoclonal B496 (henceforth abbrevi-
ated as ‘anti-CD19’), selected because of its stronger binding to
Raji cells than other antibodies (data not shown, but see
Fig S1). All the above B-cell lines bound signiﬁcant amounts of
this anti-CD19 antibody (insets in Fig 1H–N; see also FACS
data below), but its rate of uptake varied widely and was not
directly correlated to the CD19 expression level (Fig 1H–U)
and Table I. Unexpectedly, it appeared instead to negatively
correlate with CD21 expression level: the CD21-negative
(CD21
)) cell lines Ramos, DoHH2 and SuDHL-4 rapidly
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internalized a signiﬁcant amount by 3 h (Fig 1H,I and data not
shown). By contrast, the high CD21 (CD21
hi) expressors,
ARH77 and Raji, showed no signiﬁcant uptake within 3 h
(Fig 1L,M) and only little uptake compared with the above cell
lines after an overnight incubation (panels S,T). The low
CD21-expressing (CD21
lo) Namalwa and Daudi cells internal-
ized anti-CD19 much better than the high CD21-expressors,
but not as extensively as the CD21
) cells, as judged by the
remaining plasma membrane staining after 3 h Fig 1J,K) and
20 h (Fig 1R). These results were not peculiar to the B496
antibody because Raji and ARH77 cells also only slowly
internalized three other anti-CD19 antibodies, including the
widely-used HD37 monoclonal (Fig S1A,B), which has been
shown to internalize rapidly in Daudi cells (Press et al, 1989);
while Ramos cells rapidly internalized HD37 and BU12
antibodies, and FMC63 to a lesser extent (Fig S1C). Primary
human B-cells were also CD21
hi (Fig 1G), and did not
appreciably internalize anti-CD19 within 3 h (Fig 1N),
although the antibody did redistribute into patches on the
cell surface along with CD21 (Fig 2A–C), similar to in Raji
cells (Fig 1M), and did internalize to some extent within 20 h
(Fig 1U).
Expression of CD21 inhibits internalization of anti-CD19
antibodies
As CD21 is well-known to exist in a complex with CD19
(Fearon & Carroll, 2000) and CD21 is not signiﬁcantly
internalized (Fig 1), we hypothesized that CD21 bound to
CD19 and prevented anti-CD19 antibodies from internalizing.
To test this, we stably transfected CD21
) Ramos cells (Fig 2D)
with CD21, obtaining a moderately expressing clone 3 (Fig 2E)
and a highly expressing clone 1 (Fig 2F), as determined by
surface labelling with anti-CD21 antibodies. We conﬁrmed
that the transfected CD21 was indeed complexed with
endogenous CD19 by co-immunoprecipitation (Fig S2). In
support of our hypothesis, anti-CD19 was well-internalized in
Ramos cells in 3 h (Fig 2G), but less so in the moderately
CD21-expressing clone 3 (Fig 2H) and even less so in the
(A) (H) (O)
(B) (I) (P)
(C) (J) (Q)
(D) (K) (R)
(E) (L) (S)
(F) (M) (T)
(G) (N) (U)
Fig 1. Anti-CD21 antibodies are not signiﬁcantly internalized, while
anti-CD19 antibodies only internalize readily in CD21
lo or CD21
)
cells. Various B-cell lines were incubated with anti-CD21 (HB135) for
20 h at 37 C in the presence of lysosomal protease inhibitors, and the
total antibody distribution detected post ﬁxation and permeabilization
with Cy3-conjugated anti-mouse (left panels). Insets show surface
binding of anti-CD21 following 1 h incubation on ice. Ramos (A) and
DoHH2 (B) cells lack surface expression of CD21 and consequently
failed to internalize any antibody, as expected. Anti-CD21 is not sig-
niﬁcantly internalized in the low CD21-expressing Namalwa (C) or
Daudi (D) cells, or even in the higher expressing ARH77 (E) or Raji (F)
cells, or in freshly isolated primary human B-cells (G). The same cell
lines were incubated with anti-CD19 (B496) antibodies on ice for 1 h
(insets in middle panels), or at 37 C for 3 h (middle panels) or 20 h
(right panels) with detection as above. The CD21-negative cell lines
Ramos (H,O) and DoHH2 (I,P) readily internalized anti-CD19 within
3 h, while the low CD21-expressing Namalwa (J,Q) and Daudi (K,R)
cells internalized it less extensively, as judged by the faint plasma
membrane staining remaining even after 20 h uptake. The high CD21-
expressors, ARH77 and Raji did not detectably internalize anti-CD19
after 3 h (L,M), and after 20 h still had not internalized nearly as much
as the CD21-negative cells did in 3 h (S,T). Primary human B-cells did
not internalize anti-CD19 within 3 h (N), but did by 20 h (U). Vir-
tually all the cells in each ﬁeld readily internalized Alexa488-transferrin
(with the exception of transferrin-receptor negative primary B-cells),
indicating that any lack of antibody uptake was not due to loss of
viability (not shown). Gamma levels were adjusted where appropriate.
Scale bar = 20 lm.
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hi clone 1 (Fig 2I). This was not due to a general defect in
endocytosis because transferrin appeared to internalize equally
well in all three cell lines (Fig 2J–L) and uptake of antibody
RFB4 against another B-cell antigen, CD22, was similarly
unaffected (data not shown).
To conﬁrm these results more quantitatively, we ﬁrst
compared the relative surface expression of both CD21 and
CD19 on the panel of B-cell lines by ﬂow cytometry (Fig 3A).
Consistent with the immunoﬂuorescence data, SuDHL-4,
Ramos and DoHH2 cells completely lacked CD21 surface
expression; Namalwa and Daudi had low expression of CD21;
and ARH77 and Raji had higher expression. CD21 levels
decreased with time since passaging and culture age, most
likely due to shedding of the HB135 epitope, as previously
documented in Raji cells (Fremeaux-Bacchi et al, 1998), but
the overall trend of expression across the cell lines remained
the same. ARH77 cells were particularly variable over time,
(A) (B) (C)
(D) (E) (F)
(G) (H) (I)
(J) (K) (L)
(M) (N) (O)
Fig 2. Transfection of CD21 into Ramos cells impedes anti-CD19
uptake. Upper panels: freshly isolated human B-cells do not internalize
Alexa555-labeled anti-CD19 within 3 h (A, red channel in C), although
it does redistribute into patches on the cell surface (arrows) that co-
localize with Alexa488-labeled anti-CD21 added post-uptake on ice (B,
green channel in C). Scale bar = 20 lm. Lower panels: Ramos cells
(left panels) stably expressing a high (clone 1, right panels) or medium
(clone 3, middle panels) level of CD21 were incubated with Alexa555-
labeled anti-CD19 (G–I and red channel in M–O) and Alexa647-
transferrin (J–L and M–O, shown in green channel for better contrast)
for 3 h at 37 C, then chilled and incubated with Alexa488-conjugated
anti-CD21 antibodies (D–F) on ice prior to ﬁxation and imaging. Anti-
CD19 uptake is impeded by increased CD21 expression, while trans-
ferrin uptake is unaffected. Internalized anti-CD19 antibodies do not
signiﬁcantly co-localize with the recycling transferrin at this time-
point, as seen by lack of yellow colour in the respective overlaid images
(M–O). Gamma levels were adjusted where required for clarity. Scale
bar = 20 lm.
(A)
(B)
Fig 3. Quantitation of CD19 and CD21 surface levels and anti-CD19
uptake by ﬂow cytometry conﬁrms the immunoﬂuorescence results.
(A) B-cell lines were incubated on ice with 2 lg/ml mouse anti-CD21
(HB135) or mouse anti-CD19 (B496), followed by rat anti-mouse-
phycoerythrin and analyzed by ﬂow cytometry to determine surface
expression. Results are the average mean ﬂuorescence intensity (MFI)
of triplicates ± standard deviation from a representative of three
independent experiments (average of ﬁve independent experiments
shown for the more variable ARH77 cells). Shown in increasing order
of CD21 expression are: (1) SuDHL-4, (2) Ramos, (3) DoHH2, (4)
Namalwa, (5) Daudi, (6) Ramos-CD21 clone 3, (7) ARH77, (8) Raji,
(9) Ramos-CD21 clone 1. (10) Freshly isolated human B-cells have
lower ﬂuorescence values for both antigens than expected due to their
small size, but their relative ratio of CD21 to CD19 is similar to that of
ARH77 and Raji cells. Ramos-CD21 clone 1 expresses CD21 even more
highly than Raji, while Ramos-CD21 clone 3 is intermediate between
that of ARH77 and Daudi. (B) The rate of internalization of Alexa488-
anti-CD19 in Ramos ( ), Ramos-CD21 clone 1 (h), Ramos-CD21
clone 3 (4) and CD21
hi ARH77 ( ) cells was determined by pre-
binding to cells then incubating at 37 C (without washing) for the
indicated times, washing and ﬁxing either with or without surface
ﬂuorescence quenching with anti-Alexa488. Results are the average and
standard deviation of two duplicate experiments each normalized to
their respective initial surface binding levels after subtraction of
background signals.
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Raji cells, hence their designation as high expressors. Ramos-
CD21 clone 3 expressed CD21 at a level intermediate between
those of ARH77 and Daudi, while clone 1 expressed CD21
even more highly than Raji. Furthermore, while absolute
molecule numbers were not determined, Ramos-CD21 clone 1
was the only cell line with relatively higher (approximately 2Æ5-
fold) apparent binding of anti-CD21 than anti-CD19. As
expected, all the B-cell lines highly expressed CD19, especially
Raji, although both Ramos-CD21 clones had slightly lower
CD19 expression than the parental Ramos cells. By comparison
primary human B-cells exhibited lower CD19 and CD21 FACS
shifts than expected from their immunoﬂuorescence intensity
(Fig 2A,B), most likely due to their signiﬁcantly (approxi-
mately 3·) smaller surface area for antibody binding than
cultured B-cell lines (compare cell sizes in Fig 1G,F). However,
the relative apparent ratio of CD21 to CD19 in primary B-cells
was similar to those of ARH77 and Raji cells (>0Æ4), in
agreement with the slow uptake of anti-CD19 antibodies in
these cells (Fig 1N,U).
We next compared the rates of uptake of Alexa488-labeled
anti-CD19 in the two Ramos-CD21 clones, quenching any
remaining surface signal with anti-Alexa488 antibodies after
different times to measure internalized anti-CD19 by ﬂow
cytometry and normalizing the data to their relative expression
levels (Fig 3B). CD21
) Ramos cells internalized over half the
initially bound anti-CD19 antibody within 3 h, about four
times faster than the CD21
hi ARH77 cells. Ramos-CD21
hi
clone 1 internalized anti-CD19 at a similar low rate to ARH77
cells, while the more moderately expressing clone 3 internal-
ized at an intermediate rate, in agreement with the immuno-
ﬂuorescence data.
Anti-CD19 is internalized via clathrin-dependent
endocytosis and is delivered to lysosomes
The efﬁcacy of antibody-MCC-DM1 conjugates depends not
only on internalization, but also on effective delivery to
lysosomes, permitting antibody degradation and DM1 metab-
olite release (Erickson et al, 2006). We therefore investigated
the endocytic pathway taken by anti-CD19 antibodies in CD21
)
Ramos cells. Alexa488-labeled anti-CD19 uptake after 30 min
of continuous incubation was quantiﬁed in cells pre-treated
with various endocytic inhibitors and compared with Alexa488-
transferrin, which is well established to internalize via clathrin-
mediated endocytosis prior to recycling (Watts & Marsh, 1992).
Dynamin is a GTPase involved in the ﬁssion of both clathrin-
coated and caveolar vesicles (Schmid et al, 1998), whose
activity can be curbed by the novel small molecule inhibitor,
dynasore (Macia et al, 2006). Internalization of both anti-CD19
and transferrin was dramatically inhibited by both dynasore
and the clathrin inhibitor chlorpromazine, implicating clath-
rin-mediated endocytosis in anti-CD19 uptake (Fig 4A).
By contrast, the lipid raft and caveolar uptake inhibitors
methyl-b-cyclodextrin and ﬁlipin (Fig 4A) had little effect on
uptake of either anti-CD19 or transferrin, in line with the lack
of caveolin in B-cells (including Ramos, data not shown) and
lymphomas (Fra et al, 1994) and the reported lack of
redistribution of CD19 into lipid rafts upon antibody cross-
linking (Petrie et al, 2000). While the poor transfection
efﬁciency of Ramos cells precluded conﬁrmation of these
results using biological inhibitors, such as dominant negative
dynamin or Rab GTPase constructs, we were able to demon-
strate colocalization of Alexa488-anti-CD19 with transferrin
(B) (C) (D)
(E) (F) (G)
(A)
Fig 4. Anti-CD19 is internalized by dynamin-dependent, clathrin-
mediated endocytosis and is delivered to lysosomes. (A) Ramos cells
were pre-incubated for 30 min at 37 C with the following reagents:
dimethyl sulphoxide (DMSO) (1); 1 lmol/l chlorpromazine (Cpmzn)
(2), a clathrin-mediated endocytosis inhibitor; 80 lmol/l dynamin
inhibitor dynasore, preincubated for 5 min only (3); 2 mmol/l methyl-
b-cyclodextrin (MbC) (4) or 5 lg/ml ﬁlipin (5), both inhibitors of
caveolar and lipid raft endocytosis. Alexa488-anti-CD19 (black bars) or
Alexa488-transferrin (grey bars) were then added in the continuous
presence of inhibitors for 30 min and surface quenched as in Fig 3B.
Results were plotted as a percentage of uptake compared with the
DMSO control and represent the average and standard deviation of
three independent triplicate experiments. (B–D) Alexa488-anti-CD19
(green channel in B and D) was co-internalized with Alexa647-trans-
ferrin (shown in the red channel in C and D) in Ramos cells for 5 min,
surface quenched with anti-Alexa488, ﬁxed and imaged. (E–G)
Alexa488-anti-CD19 (green channel in E and G) was chased for 3 h in
Ramos cells in the presence of lysosomal protease inhibitors prior to
ﬁxation and staining with Alexa555-anti-LAMP1 (red channel in F and
G). Yellow colour in the merged images in panels D and G indicates
colocalization. Gamma levels were adjusted where necessary to better
illustrate marker overlap. Arrows indicate examples of co-localized
staining. Scale bar is 20 lm in the main panels and 6Æ7 lm in the 3·-
magniﬁed insets of the boxed region indicated in D.
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the surface signal with anti-Alexa488 antibodies; Fig 4B–D),
consistent with co-internalization in clathrin-coated vesicles.
By 20 min of chase, anti-CD19 had started to diverge from the
transferrin recycling pathway and by 60 min, partially over-
lapped with LAMP1
+ late endosomes and lysosomes (data not
shown), more extensively so after 3 h (Fig 4E–G), consistent
with the poor co-localization with transferrin seen by this
time-point (Fig 2M–O). Anti-CD19 antibodies were also
delivered to lysosomes by 3 h in all the other CD21
lo/)
internalizing B-cell lines examined (Fig S3 and data not
shown).
CD21 expression decreases the in vitro efﬁcacy of anti-
CD19-MCC-DM1 conjugates
Having established that internalized anti-CD19 antibodies end
up in lysosomes, we examined whether the inhibition of
uptake of anti-CD19 antibodies by CD21 affected the efﬁcacy
of the anti-CD19-MCC-DM1 ADC. Since the cytotoxic effect
of DM1 is mediated by preventing the assembly of the mitotic
spindle, cells were incubated with different concentrations of
the ADC for at least two to three cell divisions (3 d) to assess
its anti-proliferative effect compared with the free drug.
CD21
hi ARH77 cells showed almost no greater response to
anti-CD19-MCC-DM1 than to an equivalent concentration of
naked anti-CD19 antibody alone (Fig 5B), suggesting that the
ADC per se had little effect in this slowly internalizing cell line.
The anti-proliferative effect of naked anti-CD19 was small
but statistically signiﬁcant, albeit somewhat unexpected, as
most other naked anti-CD19 antibodies (BU12, HD37 and
FMC63) are reportedly without effect in several B-cell lines
(Chaouchi et al, 1995; Sapra & Allen, 2002; Flavell et al, 2006)
unless cross-linked or dimerized (Ghetie et al, 1997). Light
scatter analysis conﬁrmed that our anti-CD19 antibody was
devoid of detectable aggregates or dimers (data not shown).
Possible reasons for this discrepancy are that we used lower
concentrations of anti-CD19, or that our ATP detection assay
is more sensitive than the above studies, since BU12 and HD37
(but not the weaker binding FMC63 antibody) caused similar
growth inhibition to our B496 antibody (Fig S4A). In agree-
ment with previous studies using HD37 at higher concentra-
tions (Ghetie et al, 1994), this was not due to apoptosis, since
none of the naked antibodies signiﬁcantly stimulated caspase
3/7 activity within 48 h, although free DM1, and to a lesser
extent anti-CD19-MCC-DM1, did (Fig S4B).
In contrast to the lack of effect of anti-CD19-MCC-DM1 in
ARH77 cells, this ADC was much more effective in CD21
lo
Daudi cells (Fig 5C), even though these cells were no more
sensitive to free DM1. Cytotoxicity was speciﬁc because anti-
CD19-MCC-DM1 did not affect proliferation of DM1-sensi-
tive, CD19-negative Jurkat cells (Fig S4C) and Trastuzumab-
MCC-DM1 (whose target, HER2, is not expressed on any B-
cell lines) had no signiﬁcant effect any of the cell lines. The
faster internalizing CD21
) DoHH2 cells were even more
sensitive to anti-CD19-MCC-DM1 than free DM1, although
this could be partly due to the pronounced anti-proliferative
effect of the naked antibody in this cell line (Fig 5D). More
importantly, Ramos-CD21 clone 1 cells were signiﬁcantly less
responsive to CD19-MCC-DM1 than Ramos cells (Fig 5E),
despite having similar growth rates and similar sensitivities to
both the free drug and the naked anti-CD19 antibody (Fig 5F).
Speciﬁcally at 3Æ3 lg/ml anti-CD19-MCC-DM1 conjugate,
67% of Ramos cells were dead compared with only 23% of
Ramos-CD21 clone 1 (inset in Fig 5E). In fact, most, if not all
of the cytotoxicity in Ramos-CD21 cells may be attributable to
the effect of naked anti-CD19 (compare Fig 5E with F), similar
to the situation in ARH77 cells (Fig 5B). As expected, anti-
CD19-SPP-DM1, which employs a surface cleavable (reduc-
ible) SPP linker (Austin et al, 2005) and so does not depend on
lysosomal delivery for efﬁcacy, did not show any signiﬁcant
difference in killing between the Ramos and Ramos-CD21 cells
(data not shown). The rate of anti-CD19 antibody uptake
therefore does correlate with the efﬁcacy of the anti-CD19-
MCC-DM1 conjugate in vitro, and implies that such conju-
gates may be more effective at treating CD21
) or CD21
lo
CD19
+ tumours in vivo.
CD21 expression in CD19
+ lymphomas is variable
While it remains to be determined if the enhanced cytotoxicity
of anti-CD19-MCC-DM1 in the CD21
lo/) lines translates to
greater efﬁcacy in preclinical models, we sought to estimate the
level of CD21 expression in patient samples. Previous reports
suggest up to two-third of B-cell lymphomas express CD21, but
little distinction was made between low and high expressors
(Nadler et al, 1983; Scoazec et al, 1989; Gloghini & Carbone,
1993; Echeverri et al, 2002; Otsuka et al, 2004). Using anti-
CD20 to conﬁrm the identity of not otherwise speciﬁed B-cell
lymphomas (BCL), we scored the expression of CD21 as
negative ()), low (1+), or high (2+ or higher). Twenty-nine
per cent of 24 CD20
+ (and therefore presumably CD19
+; none
of the anti-CD19 antibodies recognized ﬁxed specimens to
conﬁrm this directly) BCL patients lacked detectable CD21
staining in neoplastic B-lymphocytes; another 29% had only 1+
expression; and 42% had high expression (Table IIA), which
is reasonably consistent with published results using the anti-B2
antibody to CD21 (Nadler et al, 1983). Similarly, in a set of 54
diffuse large B-cell lymphoma (DLBCL) cases, 28% of CD20
+
DLBCL samples lacked detectable CD21, a further 33% had
only low expression, and 39% had high expression (Table IIA),
conﬁrming that CD21 expression in clinical specimens is
indeed variable. Furthermore, in a limited number of frozen
DLBCL, low-grade NHL and follicular lymphoma specimens
(in which the anti-CD19 epitope is preserved), we were able to
conﬁrm by dual label immunoﬂuorescence (Fig S5) that CD21
was co-expressed in the same cells as CD19 in approximately
two-thirds of cases, with lower intensity in approximately half
of those, and no expression in the remaining one-third of cases
(Table IIB).
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We have shown that B-cell lines do not appreciably internalize
the HB135 anti-CD21 antibody, even when CD21 is highly
expressed, as in ARH77, Raji and primary human B-cells. This
most likely explains the lack of effect of anti-CD21-MCC-DM1
(Fig 5A), since internalization is required for drug release from
SMCC-DM1 conjugates (Erickson et al, 2006; Polson et al,
2007). Our data are consistent with the lack of anti-CD21
internalization in B-cells observed in an earlier study (Barrault
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Fig 5. Anti-CD19-MCC-DM1 is less efﬁcacious in high CD21 expressing cells. (A) CD21
hi Raji were incubated for 3 d with anti-CD21-MCC-DM1
(s), negative control Trastuzumab-MCC-DM1 ( ), free L-DM1 dimer ( ) or naked anti-CD21 antibodies (•) and assessed for viability by
measuring ATP levels. CD21
hi ARH77 (B), CD21
lo Daudi (C), and CD21
) DoHH2 cells (D) were incubated for 3 d with anti-CD19-MCC-DM1 (¤),
negative control Trastuzumab-MCC-DM1 ( ), free L-DM1 dimer ( ) or naked anti-CD19 antibodies (·) and assessed for viability by measuring
ATP levels. (E) Ramos (solid symbols and lines) and Ramos-CD21 clone 1 (open symbols and dashed lines) were treated with anti-CD19-MCC-DM1
(¤,)) or free DM1 ( ,h) as in B-D. Inset bar graph shows percentage killing of Ramos (¤) and Ramos-CD21 clone 1 ()) at the highest anti-CD19-
MCC-DM1 concentration used (3Æ33 lg/ml). (F) Ramos (solid symbols and lines) and Ramos-CD21 clone 1 (open symbols and dashed lines) were
treated with control Trastuzumab-MCC-DM1 ( ,4), free DM1 ( ,h) or unconjugated anti-CD19 (·) as in B. Data are shown in all panels as a
percentage viability of untreated control cells (mean and standard deviation of three independent duplicate experiments) versus ADC concentration
in lg/ml on the lower x-axes or free DM1 concentration in M on the upper x-axes. * denotes data points statistically different (P <0 Æ01) from the
control untreated cells using the analysis of variance (anova) test. +, data points signiﬁcantly different between Ramos and Ramos-CD21 clone 1 cells
by anova analysis (P <0 Æ01). The CD21
hi Raji and Ramos-clone 1 cells showed greater resistance (compared with their respective free L-DM1
sensitivities) than the CD21
) Ramos, DoHH2 and CD21
lo Daudi cells.
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induced by binding of its ligands, C3d or EBV (Tedder et al,
1986; Perrin-Cocon et al, 2004) or when it is expressed in the
absence of CD19 and the B-cell receptor in 293 cells (Tessier
et al, 2006).
We also found that the internalization of four different anti-
CD19 antibodies was interestingly negatively correlated with
CD21 expression such that CD21
hi Raji, ARH77 and normal
B-cells failed to signiﬁcantly internalize, while cells with low
CD21, i.e. Daudi, Namalwa (also Granta, data not shown), or
no CD21, i.e. Ramos, DoHH2 (and SuDHL-4, data not
shown), internalized anti-CD19 rapidly (within 5–20 min).
Conversely, siRNA-mediated knockdown of CD21 in Raji cells
permitted anti-CD19 uptake in this cell line (data not shown).
There was no correlation of anti-CD19 uptake with the other
major B-cell markers, CD20, CD22 or CD79b (Table I); nor
did CD21 expression correlate with uptake of antibodies to any
of those proteins (data not shown). Since at steady-state CD19
was only detectable at the cell surface by immunoﬂuorescence
(data not shown), it is likely that the anti-CD19 antibodies
trigger internalization of CD19 in CD21
lo/) cells by cross-
linking of CD19 to itself, rather than ‘catching a ride’ on
constitutively internalizing CD19. Signiﬁcantly, Ramos cells
transfected with CD21 no longer displayed such rapid uptake
of anti-CD19 antibodies, presumably because CD21 forms
a non-covalent complex with CD19 (Tedder et al, 1994;
Fearon & Carroll, 2000), as shown by immunoprecipitation.
One explanation could be that complex formation prevents self
cross-linking of CD19 by anti-CD19 antibodies, retarding their
internalization. Note that anti-CD19 and anti-CD21 antibodies
(including B496 and HB135, data not shown) can be made to
internalize in CD21
hi Raji and ARH77 cells by cross-linking
with anti-mouse secondaries (Pulczynski et al, 1993; Sieber
et al, 2003), but this is probably irrelevant to antibody-MCC-
DM1 therapy, as the antibodies would be humanized prior to
clinical trials and anti-human antibodies would not be present
in the patients. Even so, consistent with our hypothesis,
Pulczynski et al (1993) demonstrated faster internalization of
cross-linked anti-CD19 (B4) in the CD21
) pre-B blast cell line
NALM6 than in CD21
hi Raji cells, despite these cell lines
having similar CD19 levels.
Our data are in agreement with the observed uptake of
various other anti-CD19 antibodies in CD21
) NALM-6 and
CD21
lo Daudi and Namalwa cells (Nadler et al, 1983; Uckun
et al, 1988; Press et al, 1989; Goulet et al, 1997; Sapra & Allen,
2002). Our results may also explain the lack of anti-CD19
uptake in B-cells from patients with B-cell chronic lymphocytic
leukemia (B-CLL) (Sieber et al, 2003), since these are mostly
CD21
+ (Nadler et al, 1983; Lopez-Matas et al, 2000; Cherukuri
et al, 2001a). Furthermore, antibodies to both components of
the CD19/CD21 complex were found not to internalize in
murine B-cell lymphoma CH27 or splenic B-cells even after
cross-linking to antigen or complement (Cherukuri et al,
2001a,b). We took precautions to avoid any CD19-indepen-
dent uptake of anti-CD19 by Fc-c receptors (as measured by
Vervoordeldonk et al (1996)) by including human Fc-receptor
block in all our experiments.
The actual endocytic pathway responsible for anti-CD19
uptake in all these studies has not been characterized, with the
exception of its visualization by electron microscopy in
unidentiﬁed plasmalemmal pits and eventually in lysosomes
following secondary antibody-mediated cross-linking in Raji
and NALM-6 cells (Pulczynski et al, 1993). We found that, in
the absence of CD21, non-cross-linked anti-CD19 most prob-
ably internalizes via clathrin-mediated endocytosis, based on its
colocalization at early time-points (5 min) with the clathrin
cargo transferrin and inhibition of uptake of both proteins with
the clathrin inhibitor chlorpromazine. Consistent with this,
CD19 has two potential tyrosine-based internalization motifs
(YEDM and YENM) in its cytoplasmic tail that could be
predicted to bind the clathrin adaptor AP-2 (Bonifacino &
Traub, 2003). In CD77 (globotriaosylceramide)-positive Daudi
Table IIA. Immunohistochemical analysis of CD21 expression in
CD20
+ B-cells of formalin-ﬁxed, parafﬁn-embedded lymphoma
samples.
Lymphoma type CD21
)* CD21 1+  CD21 ‡ 2+ 
BCL 7/24 (29) 7/24 (29) 10/24 (42)
DLBCL 15/54 (28) 18/54 (33) 21/54 (39)
Values are expressed as n (%).
BCL, not otherwise speciﬁed B-Cell lymphoma; DLBCL, diffuse large
B-cell lymphoma.
*CD21
), CD21 staining is absent from neoplastic CD20
+ B-lympho-
cytes.
 1+, weak CD21 expression in CD20
+ B-lymphocytes.
 ‡2+, high 2+ or 3+ expression of CD21 in CD20
+ B-lymphocytes.
Table IIB. Dual immunoﬂuorescence (IF) analysis of CD19 and CD21
expression in frozen lymphoma specimens.
Lymphoma type CD21
)* CD21 1+ 
CD21 ‡
2+ 
CD21 <
CD19§
DLBCL
a 3/7 (43) 1/7 (14) 3/7 (43) 3/7 (43)
Low grade NHL 3/7 (43) 2/7 (29) 2/7 (29) 4/7 (57)
Follicular lymphoma 1/3 (33) 2/3 (67) 0/3 (0) 2/3 (67)
Values are expressed as n (%).
DLBCL, diffuse large B-cell lymphoma; NHL, Non-Hodgkin lym-
phoma.
*CD21), CD21 staining is absent from neoplastic CD19
+ B-lympho-
cytes (an example of such a specimen is shown in Fig S5B).
 1+, weak CD21 expression in CD19
+ B-lymphocytes (an example
being shown in Fig S5C).
 At least 2+, 2+ or 3+ expression of CD21 in CD19
+ B-lymphocytes
(see example in Fig S5D).
§CD21 < CD19, CD21 IF score is lower than CD19 IF score (e.g.
Fig S5C). Note that the different antibody afﬁnities were not taken into
account for this analysis; CD21 and CD19 levels were independently
scored as negative to 3+ across all the tumour samples, then the ﬁnal IF
scores for the two antibodies were reviewed.
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endoplasmic reticulum and nuclear envelope (Khine et al,
1998), but our non-cross-linked anti-CD19 showed no such
localization, being transported instead to late endosomes and
lysosomes within 1–3 h. Furthermore, antibody uptake showed
no correlation with CD77 status (Table I), with CD77
)
Namalwa cells showing very similar uptake kinetics and
antibody distribution in lysosomes to CD77
+ Daudi cells
(which express similar CD21 levels).
The observed decrease in anti-CD19 antibody internaliza-
tion by expression of CD21 also resulted in decreased
sensitivity to the anti-CD19-MCC-DM1 ADC, conﬁrming
earlier results that efﬁcient lysosomal delivery is required for
activity of antibody-MCC-DM1 conjugates (Erickson et al,
2006; Polson et al, 2007). As the antibody must be degraded in
lysosomes to release the free drug (or MCC-DM1 linked to the
conjugating lysine in this case; Erickson et al, 2006), we
propose that a rapid rate of lysosomal delivery is probably
required to ensure a sufﬁcient concentration gradient of
released drug to diffuse across the lysosomal membrane into
the cytoplasm and reach the target microtubules. In the case of
the slowly internalizing CD21
hi cells, lysine-MCC-DM1 is
probably not released quickly enough from anti-CD19 to
generate a sufﬁcient diffusion gradient for effective microtu-
bule inhibition and cytotoxicity, most likely being inactivated
in the lysosomes instead.
The low level of anti-proliferative activity of anti-CD19-
MCC-DM1 in Ramos-CD21 clone 1 cells was partially, if not
mostly, due to a naked antibody effect, which, unlike the
MCC-DM1 conjugate, was less effective at high concentrations
for reasons that are unclear. This naked anti-CD19 effect was
unrelated to both CD21 and CD19 expression levels, occurring
most markedly in DoHH2, SuDHL-4 and ARH77 cells, less so
Ramos (and Ramos-CD21) and not at all in Raji or Daudi cells
(summarized in Table I). At least one other naked anti-CD19
antibody (HB-12b) has been previously shown to inhibit
proliferation of other B-cell lines Arent and OCI-LY8,
expressing different levels of CD19 (Bradbury et al, 1992).
Our immunohistochemical results show that approximately
one-third of DLBCL (and also unclassiﬁed BCL) patients lack
CD21 expression, with another approximately one-third
having low CD21 expression, in agreement with earlier
analyses (Nadler et al, 1983; Otsuka et al, 2004). Thus, if our
in vitro cytotoxicity data correctly predicts in vivo efﬁcacy
(which has yet to be determined), only a subpopulation of
lymphoma patients would have tumours suitable for treatment
with internalization-dependent anti-CD19 ADCs. This sug-
gests that it may be worthwhile to examine biopsies from past
and future trials for CD21 expression (as well as CD19
expression) to determine if CD21 levels do indeed predict
patient response to internalization-dependent anti-CD19 ADC
therapy.
In summary, we have shown that CD21 expression signif-
icantly retards the internalization of anti-CD19 antibodies and
decreases the cytotoxicity of anti-CD19-MCC-DM1 conjugates.
While CD21 expression may not be the only ‘resistance factor’
for anti-CD19-MCC-DM1 therapy, these data should aid the
selection of suitable preclinical lymphoma xenograft models for
testing this ADC, with CD21
) or CD21
lo models being expected
to show greater efﬁcacy. Our results should be generally
applicable to other internalization-dependent anti-CD19 ADCs
(Sapra & Allen, 2002). However, DM1 conjugation does not
alter the internalization of anti-CD19 antibody (data not
shown), whereas ricin conjugation to another anti-CD19
antibody increases its internalization, possibly via toxin
dimerization and CD19 cross-linking (Goulet et al, 1997).
Furthermore, since CD21 is only expressed in approximately
two-third of B-cell lymphomas and only at low levels in half of
those (Table I), our results may even be of clinical importance
in selecting appropriate patients for anti-CD19 ADC therapy.
Clearly, this is an avenue of future research worth investigating.
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